Citations

Showing 10 of 108104 citations.

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Progressive Glioblastoma in Adults: Update of the 2014 Guidelines
Patrick, Hayes H. , Goodman, Abigail , Germano, Isabelle M. , Johnson, Derek R. , Ziu, Mateo , Ormond, David Ryan , Olson, Jeffrey J.

Mayo Clinic

Neurosurgery | April 15, 2022 | Volume: 90 | Issue: 5 | Pages: e112-e115

10.1227/neu.0000000000001903 | PMID 35426875 Get It

BACKGROUND: The Institute of Medicine best practice recommendation to review guidelines every 5 years is followed by the Congress of Neurological Surgeons Guidelines Committee. The aim of this work was to provide an updated literature review and evidence-based recommendations on the topic of diagnosis and treatment of patients with progressive glioblastoma (pGBM). OBJECTIVE: To review the literature published since the last guidelines on pGBM dated 2014, with literature search ending in June 2012. METHODS: PubMed, Embase, and Cochrane were searched for the period July 1, 2012, to March 31, 2019, using search terms and search strategies to identify pertinent abstracts. These were then screened using published exclusion/inclusion criteria to identify full-text review articles. Evidence tables were constructed using data derived from full-text reviews and recommendations made from the evidence derived. RESULTS: From the total 8786 abstracts identified by the search, 237 full-text articles met inclusion/exclusion criteria and were included in this update. Two new level II recommendations derived from this work. For the diagnosis of patients with GBM, the use of diffusion-weighted images is recommended to be included in the magnetic resonance images with and without contrast used for surveillance to detect pGBM. For the treatment of patients with pGBM, repeat cytoreductive surgery is recommended to improve overall survival. An additional 21 level III recommendations were provided. CONCLUSION: Recent published literature provides new recommendations for the diagnosis and treatment of pGBM. The Central Nervous System Guidelines Committee will continue to pursue timely updates to further improve the care of patients with diagnosis. https://www.cns.org/guidelines/browse-guidelines-detail/guidelines-management-of-progressive-glioblastoma
Clostridioides difficile infection: curbing a difficult menace
Khanna, Sahil , Pardi, Ryan

Mayo Clinic

Therapeutic Advances in Gastroenterology | April 15, 2022 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17562848221089906 | PMID 35450386 Get It

Use of Self-Collected Saliva Samples for the Detection of SARS-CoV-2
Sogbesan, Kehinde, Sogbesan, Taiwo, Hata, D. Jane , White, Edward L, Daniel, Wyeth, Gasson, Samuel L, Jones, Dylan S, Vicari, Brittany R, Siclen, Carleen P Van, Palmucci, Carla, Marquez, Christopher P. , Parkulo, Mark A. , Thielen, Kent R. , Van Siclen, Carleen P, Nassar, Aziza

Mayo Clinic

Laboratory Medicine | April 15, 2022 | Volume: 53 | Issue: 6 | Pages: 580-584

10.1093/labmed/lmac051 | PMID 35672905 Get It

Abstract Objective Using a US Food and Drug Administration (FDA) emergency use authorization (EUA) reverse transcription polymerase chain reaction (RT-PCR) method, we examined the analytic performance accuracy of saliva specimens as compared to nasopharyngeal (NP) specimens in symptomatic patients. Correlation between test results and symptoms was also evaluated. Methods Over a 5-week period in 2020, 89 matched saliva and nasopharyngeal swabs were collected from individuals exhibiting symptoms consistent with SARS-CoV-2. Specimens were tested with an FDA EUA-approved RT-PCR method, and performance characteristics were compared. Results The concordance rate between saliva and nasopharyngeal testing was 93.26%. The mean cycle threshold value of saliva when compared to the NP specimen was 3.56 cycles higher. As compared to NP swab, saliva testing demonstrates acceptable agreement but lower sensitivity. Conclusion When compared to a reference method using NP swabs, the use of saliva testing proved to be a reliable method. Self-collected saliva testing for SARS-CoV-2 allows for a viable option when trained staff or collection materials are in short supply.
Understanding Drug Sensitivity and Tackling Resistance in Cancer
Tyner, Jeffrey W. , Haderk, Franziska, Kumaraswamy, Anbarasu , Baughn, Linda B., Ness, Brian Van, Liu, Song, Marathe, Himangi, Alumkal, Joshi J. , Bivona, Trever G., Chan, Keith Syson, Nelson, Peter S. , Druker, Brian J , Hutson, Alan D , Nelson, Peter S , Sawyers, Charles L. , Willey, Christopher D , Tyner, Jeffrey W. , Haderk, Franziska, Kumaraswamy, Anbarasu , Baughn, Linda B., Ness, Brian Van, Liu, Song, Marathe, Himangi, Alumkal, Joshi J , Bivona, Trever G., Chan, Keith Syson

Mayo Clinic

Cancer Research | April 15, 2022 | Volume: 82 | Issue: 8 | Pages: 1448-1460

10.1158/0008-5472.can-21-3695 | PMID 35195258 Get It

Abstract Decades of research into the molecular mechanisms of cancer and the development of novel therapeutics have yielded a number of remarkable successes. However, our ability to broadly assign effective, rationally targeted therapies in a personalized manner remains elusive for many patients, and drug resistance persists as a major problem. This is in part due to the well-documented heterogeneity of cancer, including the diversity of tumor cell lineages and cell states, the spectrum of somatic mutations, the complexity of microenvironments, and immune-suppressive features and immune repertoires, which collectively require numerous different therapeutic approaches. Here, we describe a framework to understand the types and biological causes of resistance, providing translational opportunities to tackle drug resistance by rational therapeutic strategies.
Catheter ablation of atrial fibrillation: recent advances and future challenges
Hindricks, Gerhard , Packer, Douglas L.

Mayo Clinic

EP Europace | April 14, 2022 | Volume: 24 | Issue: Supplement_2 | Pages: ii1-ii2

10.1093/europace/euac035 | PMID 35661864 Get It

Predictors of adverse events and early mortality after esophageal stent placement in a low resource setting: a series of 3823 patients in Kenya
Parker, Robert K. , Lando, Justus , Simel, Ian , Chol, Nyail, Ranketi, Sinkeet, Chepkwony, Robert, Pyego, Linus, Chepkirui, Caren, Chepkemoi, Winnie, Fleischer, David E., Topazian, Mark , Burgert, Steve, White, Russell E., Fleischer, David, Mwachiro, Michael , Dawsey, Sanford M. , Burgert, Stephen L.

Mayo Clinic

Endoscopy International Open | April 14, 2022 | Volume: 10 | Issue: 04 | Pages: E479-E487

10.1055/a-1783-9829 | PMID 35433219 Get It

Abstract Background and study aims Dysphagia from esophageal cancer may be palliated with self-expanding metallic stents (SEMS). Controversy exists about the use of dilation before SEMS deployment. Patients and methods We performed a retrospective cohort study of patients who had SEMS placement without fluoroscopy for palliation at Tenwek Hospital in Bomet, Kenya between January 1999 and April 2019. The primary outcome was any serious adverse event (AE) (chest pain, stent migration, perforation, bleeding, or all-cause mortality) within 30 days of the procedure. Various demographic and clinical characteristics, and procedural details, were examined as risk factors. Technical success, defined as correct SEMS placement, and clinical success, defined as dysphagia score improvement without 30-day mortality, were examined. Results A total of 3823 patients underwent SEMS placement, with 2844 (74.4 %) placed in the second decade of the study. Technical and clinical success were achieved in 97.2 % and 95.5 %, respectively, with mean dysphagia scores improving from 3.4 (SD 0.6) to 0.9 (SD 1.3) post-stent placement. AEs occurred in 169 patients (4.4 %). AEs, specifically perforations, were associated with dilation to greater than 36F in the first decade. Perforation rates decreased from the first (4.1 %) to the second decade (0.2 %). Only 30% had complete 30-day follow-up data. Conclusions SEMS placement is a safe, effective method of palliating malignant dysphagia, with low rates of AEs and 30-day mortality and high rates of clinical and technical success. Dilation can facilitate placement of SEMS without fluoroscopy but should not be performed above 36F due to the risk of perforation.
Does endoscopic mean safer? A comparison of the short-term safety of endoscopic versus laparoscopic bariatric therapies
Fayad, Lea , Schweitzer, Michael , Itani, Mohamad I. , Farha, Jad , Hedjoudje, Abdellah , Badurdeen, Dilhana, Kumbhari, Vivek

Mayo Clinic

Endoscopy International Open | April 14, 2022 | Volume: 10 | Issue: 04 | Pages: E307-E310

10.1055/a-1783-8573 | PMID 35433204 Get It

Abstract Background and study aims There is minimal research on real-world, large-volume data comparing endoscopic bariatric therapy (EBT) to laparoscopic bariatric therapy (LBT). This study aimed to compare 30-day postoperative morbidity and mortality outcomes of primary EBT vs LBT using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. Patients and methods Patients aged 18 to 80 with body mass index (BMI) 35 to 40 kg/m2 undergoing primary procedures were included. Propensity score matching 1:50 was performed for EBT versus LBT based on age, sex, and BMI. Results We matched 211 EBTs with 9,059 LBTs. Operative length (63.9, 95 % confidence interval [CI]: 57.9, 69.8 versus 81.1, 95 % CI: 80.1, 82.1) and length of stay (0.49 days, 95 % CI: 0.29, 0.69 versus 1.43 days, 95 % CI: 1.41, 1.45) were significantly lower in the EBT group than the LBT group. There was no difference between EBT and LBT in the odds of readmission (odds ratio [OR] = 0.31, 95 % CI: 0.08, 1.25), reoperation (OR = 0.39, 95 % CI: 0.05, 2.84), or reintervention (OR = 0.98, 95 % CI: 0.24, 3.99). After controlling for chronic obstructive pulmonary disease, sleep apnea, history of myocardial infarction, hypertension requiring medications, and diabetes, EBT continued to be associated with lower odds of having any adverse event (AE) than LBT, with an OR of 0.34 (95 % CI: 0.16, 0.69). Subgroup analysis comparing EBT to laparoscopic sleeve gastrectomy (LSG) showed that EBT was associated with a lower risk having any AE than LSG, with an OR of 0.39 (95 % CI: 0.19, 0.79). Conclusions EBT is associated with a lower 30-day AE rate and shorter procedural length and length of stay than LBT, with similar rates of readmission, reintervention, and reoperation.
Endoscopic ultrasound-guided gastroenterostomy versus surgical gastrojejunostomy in treatment of malignant gastric outlet obstruction: Systematic review and meta-analysis
Bomman, Shivanand , Ghafoor, Adil , Sanders, David J. , Jayaraj, Mahendran , Chandra, Shruti , Krishnamoorthi, Rajesh

Mayo Clinic

Endoscopy International Open | April 14, 2022 | Volume: 10 | Issue: 04 | Pages: E361-E368

10.1055/a-1783-8949 | PMID 35433211 Get It

Abstract Background and study aims Palliative treatment of malignant gastric outlet obstruction (GOO) has conventionally been with surgical gastrojejunostomy (SGJ). Advent of devices like lumen apposing metal stents has made endoscopic ultrasound-guided gastroenterostomy (EUS-GE) a potential alternative to SGJ for these patients. We performed a systematic review and meta-analysis of studies that compared outcomes of EUS-GE versus SGJ. Methods We performed a comprehensive systematic search of multiple electronic databases and conference proceedings through January 2021 and identified six studies that compared outcomes of EUS-GE versus SGJ in the management of malignant GOO. The rates of technical success, clinical success, and AEs were analyzed, and pooled odds ratios were calculated using random effects model. Results Six studies were included in our analysis with a total of 484 patients, of which 291 underwent EUS-GE and 193 underwent SGJ. The technical success rate of SGJ was superior to EUS-GE (OR = 0.195; 95 %CI:0.054–0.702; P = 0.012; I2 = 0). The clinical success of EUS-GE was statistically similar to SGJ (OR = 1.566; 95 %CI:0.585–4.197; P = 0.372; I2 = 46.68 %). EUS-GE had significantly fewer AEs compared to SGJ (OR = 0.295; 95 %CI:0.172–0.506; P < 0.005; I2 = 0). Among studies which reported reintervention rates, EUS-GE was statistically similar to SGJ (OR = 0.587; 95 %CI:0.174–1.979; P = 0.390, I2 = 54.91). Minimal to moderate heterogeneity was noted in the analyses. Conclusions EUS-GE has equivalent clinical success and reintervention rates, but significantly lower adverse events compared to SGJ. When feasible, EUS-GE appears to be an effective and safe alternative to SGJ for palliative management of malignant GOO.
Endoscopic submucosal dissection for colorectal dysplasia in inflammatory bowel disease: a US multicenter study
Ngamruengphong, Saowanee , Aihara, Hiroyuki , Friedland, Shai , Benias, Petros C. , Draganov, Peter V. , Kumta, Nikhil A. , Borman, Zachary A. , Dixon, Rebekah E. , Marion, James F., Tomizawa, Yutaka , Mohapatra, Sonmoon , Charabaty, Aline , Lazarev, Mark , Figueroa, Esteban, Hanada, Yuri , Song, Louis M. Wong Kee , Wong Kee Song, Louis M, Nishimura, Makoto , Faleck, David M. , Yang, Dennis J. , D'Souza, Lionel S. , Jit, Simran, Parian, Alyssa M. , Wang, Andrew Y.

Mayo Clinic

Endoscopy International Open | April 14, 2022 | Volume: 10 | Issue: 04 | Pages: E354-E360

10.1055/a-1783-8756 | PMID 35433226 Get It

Abstract Background and study aims In patients with inflammatory bowel disease (IBD), endoscopically visible lesions with distinct borders can be considered for endoscopic resection. The role of endoscopic submucosal dissection (ESD) for these lesions is not well defined because of a paucity of data. We aimed to evaluate the outcomes of colorectal ESD of dysplastic lesions in patients with IBD across centers in the United States. Patients and methods This was a retrospective analysis of consecutive patients with IBD who were referred for ESD of dysplastic colorectal lesions at nine centers. The primary endpoints were the rates of en bloc resection and complete (R0) resection. The secondary endpoints were the rates of adverse events and lesion recurrence. Results A total of 45 dysplastic lesions (median size 30mm, interquartile range [IQR] 23 to 42 mm) in 41 patients were included. Submucosal fibrosis was observed in 73 %. En bloc resection was achieved in 43 of 45 lesions (96 %) and R0 resection in 34 of 45 lesions (76 %). Intraprocedural perforation occurred in one patient (2.4 %) and was treated successfully with clip placement. Delayed bleeding occurred in four patients (9.8 %). No severe intraprocedural bleeding or delayed perforation occurred. During a median follow-up of 18 months (IQR 13 to 37 months), local recurrence occurred in one case (2.6 %). Metachronous lesions were identified in 11 patients (31 %). Conclusions ESD, when performed by experts, is safe and effective for large, dysplastic colorectal lesions in patients with IBD. Despite the high prevalence of submucosal fibrosis, en bloc resection was achieved in nearly all patients with IBD undergoing ESD. Careful endoscopic surveillance is necessary to monitor for local recurrence and metachronous lesions after ESD.